Αποτελέσματα Αναζήτησης
De-escalation of anthracycline-containing regimens is gaining popularity. The US Oncology 9735 reported that 4 cycles of docetaxel and cyclophosphamide (TCx4) was superior to 4 cycles of doxorubicin and cyclophosphamide (ACx4) in terms of disease-free survival (DFS) and overall survival (OS).
19 Απρ 2022 · Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
17 Αυγ 2015 · The widespread use of adjuvant systemic therapy has contributed to reduced breast cancer mortality rates. Adjuvant cytotoxic chemotherapy regimens have evolved from single alkylating agents to polychemotherapy regimens incorporating anthracyclines and/or taxanes.
28 Οκτ 2021 · Biological therapies have changed the face of oncology by targeting cancerous cells while reducing the effect on normal tissue. This publication focuses mainly on new therapies that have contributed to the advances in treatment of certain malignancies.
2 Σεπ 2021 · To analyze the cost-effectiveness of Doxorubicin/cyclophosphamide/Paclitaxel/trastuzumab (AC-TH) and Docetaxel/Carboplatin/trastuzumab (TCH). Methods. A Markov model was built to simulate the process of breast cancer events and death occurred in both AC-TH and TCH armed patients and to choose a suitable chemotherapy method.
15 Σεπ 2014 · Systems biology approaches help understand how complex cancer-associated deregulations coordinately shape malignant states and phenotypes, sometimes across multiple biological scales.
31 Ιουλ 2017 · An analysis of the SEER-Medicare database shows that outcomes and healthcare costs for the two chemotherapy regimens are similar, with one difference.
